Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pivekimab sunirine plus venetoclax and azacitidine in newly diagnosed AML ineligible for intensive chemotherapy
NCT07581002Phase 3Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Jun 2026
- Primary completion
- Jun 2032
- Countries
- 7
01
Overview
A Phase 3 trial of pivekimab sunirine in acute myeloid leukemia (AML), sponsored by AbbVie Inc.. Started Jun 2026; status: recruiting.
02
Drugs
pivekimab sunirine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07581002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07581002.